APRT

Adenine phosphoribosyltransferase · P07741 · APRT on Sugi Atlas →

453 patent compounds predicted against APRT, 312 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Crenolanib (SCHEMBL2730601)	1.00	1/20
Crenolanib (SCHEMBL29350134)	1.00	1/20
Crenolanib (SCHEMBL29352568)	1.00	1/20
Crenolanib (SCHEMBL30002138)	1.00	1/20
SCHEMBL22567082	0.86	1/20
SCHEMBL5662568	0.85	1/20
Crenolanib (SCHEMBL4681285)	0.85	1/20
Crenolanib (SCHEMBL29352554)	0.85	1/20
Crenolanib (SCHEMBL29361948)	0.85	1/20
SCHEMBL27030604	0.85	1/20
SCHEMBL30775111	0.85	1/20
SCHEMBL23026363	0.82	1/20
SCHEMBL3191766	0.80	1/20
SCHEMBL27030775	0.80	1/20
SCHEMBL30441378	0.80	1/20
SCHEMBL3180117	0.79	1/20
SCHEMBL3189249	0.78	1/20
SCHEMBL3190082	0.78	1/20
SCHEMBL3190135	0.78	1/20
SCHEMBL3182258	0.76	1/20

Clinical trials — most relevant to APRT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis	PHASE3	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma	PHASE2	UNKNOWN
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer	PHASE2	UNKNOWN
Capecitabine and Temozolomide for Neuroendocrine Cancers	PHASE2	COMPLETED
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung	PHASE2	COMPLETED
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients	PHASE2	COMPLETED
Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate	PHASE1/PHASE2	UNKNOWN
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene	PHASE2	COMPLETED
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer	PHASE2	COMPLETED
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer	PHASE2	UNKNOWN
Thiopurine EnhAnced Maintenance Therapy	PHASE1/PHASE2	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg	PHASE1	COMPLETED
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma	PHASE1	RECRUITING
Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers	PHASE1	COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer	PHASE1	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	nan	UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia	nan	COMPLETED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
An EQA Scheme for TPMT Activity and Thiopurine Metabolites	nan	UNKNOWN
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting	nan	COMPLETED
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.	nan	COMPLETED
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a APRT binder may also engage these)

Protein	Name	Similarity
Q56JW4	—	1.000	Q56JW4 →
P47958	—	1.000	P47958 →
Q64414	—	0.999	Q64414 →
P47952	—	0.998	P47952 →
P36972	—	0.998	P36972 →
P47957	—	0.997	P47957 →
P08030	—	0.997	P08030 →
Q64427	—	0.996	Q64427 →
P47956	—	0.994	P47956 →
P54363	—	0.986	P54363 →
Q145V4	—	0.985	Q145V4 →
A9AF06	—	0.985	A9AF06 →
A4JHX7	—	0.985	A4JHX7 →
Q39CV8	—	0.984	Q39CV8 →
A7H8F4	—	0.984	A7H8F4 →
A1KV71	—	0.983	A1KV71 →
B2JCQ7	—	0.983	B2JCQ7 →
A9M1N3	—	0.983	A9M1N3 →
A7NG77	—	0.982	A7NG77 →
Q1BTI4	—	0.982	Q1BTI4 →
Q83M42	—	0.982	Q83M42 →
B8JDQ9	—	0.982	B8JDQ9 →
B4UE87	—	0.982	B4UE87 →
A5GSL0	—	0.982	A5GSL0 →
B1JYN1	—	0.982	B1JYN1 →
B5Z3X9	—	0.981	B5Z3X9 →
Q8XD48	—	0.981	Q8XD48 →
C6E585	—	0.981	C6E585 →
Q8Z8T4	—	0.981	Q8Z8T4 →
A6WPL2	—	0.981	A6WPL2 →